Colorectal Cancer
Advertisement
A recent observational study determined if there is a correlation between the improvement of ADR and lower rates of CRC.
The designation is based on positive results from an ongoing collaborative trial between GSK and MSK Cancer Center.
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
Neoadjuvant nivolumab plus relatlimab led to a pathologic response rate of 96%.
The CodeBreaK 101 study assessed the safety and efficacy of soto, pani, and FOLFIRI for KRAS G12C-mutated mCRC.
Cetuximab rechallenge guided by liquid biopsy improved response and disease control rates in RAS wild-type mCRC.
1L zanidatamab plus chemo with or without bevacizumab demonstrated antitumor activity and manageable safety in mCRC.
The latest data from the RECAST trial shed light on FOLFIRI plus RAM for patients with metastatic CRC.
Dr. Grady opines on whether colonoscopy, stool-based, or blood-based tests will be integrated into CRC screening guidelines.
Dr. Grady discusses ECLIPSE for colorectal cancer screening and the findings that led to approval of the Shield test.
Dr. Lieu breaks down his top uses of AI in GI oncology today, as well as their projected applicability in the near future.
There is little research on the efficacy of adding oxaliplatin to treat older patients with the disease.
The systematic review included data from 12 randomized controlled trials, 2 systematic reviews, and 1 nonrandomized study.
Trastuzumab deruxtecan has provided encouraging activity for treatment-refractory HER2+ RAS and BRAF wild-type mCRC.
Investigators calculated the C-for-benefit to evaluate evidence for HTE.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.